SHP681

SHP681 is a recombinant fusion protein that acts as a glucagon-like peptide 2 (GLP-2) analog fused to an Fc domain. It was developed for the treatment of gastrointestinal disorders, specifically short bowel syndrome. The drug functions as a modulator of the glucagon-like peptide 2 receptor (GLP-2R), aiming to enhance intestinal growth and function by mimicking endogenous GLP-2 activity. Originally developed by Shire and later Takeda following acquisition, SHP681 reached phase 1 clinical trials but development was discontinued after completion of early studies[1][3][6].

Other names

SHP-681SHP681SHP 681TAK-681TAK681TAK 681GLP-2 Analog-Fc FusionGLP2 Analog-Fc FusionGLP 2 Analog-Fc Fusion